About
Evozyne is a Chicago-based AI-native biotechnology company that harnesses generative AI to design de novo therapeutic proteins for immune-mediated diseases. At the core of its platform are two integrated systems: EvoGen, an AI engine that learns the relationship between protein sequences and function to design optimized candidates for potency, stability, specificity, and reduced immunogenicity; and EvoLab, a high-throughput experimental facility that synthesizes and evaluates thousands of protein candidates per design cycle, generating large proprietary datasets that continuously improve the AI models. Evozyne's therapeutic pipeline focuses on immunology, including IgG proteases, next-generation cytokines, and respiratory disease candidates — areas where existing treatments leave many patients without adequate relief or with diminishing efficacy over time. The platform's closed-loop design-build-test cycle accelerates the translation of AI-designed proteins toward clinical evaluation. The company has demonstrated platform performance through peer-reviewed research, including publications in PNAS (ProT-VAE, developed with NVIDIA) and microPublication Biology, showcasing superior thermotolerance and functional activity gains. Evozyne is positioned at the frontier of computational protein design and AI-driven drug discovery, making it relevant for pharma partners, biotech investors, and research institutions seeking next-generation biologic therapeutics.
Key Features
- EvoGen AI Design Engine: A generative AI platform that learns from protein sequence-function relationships to design novel proteins optimized for potency, stability, specificity, and immunogenicity.
- EvoLab High-Throughput Facility: An experimental lab that synthesizes and evaluates thousands of protein candidates per design cycle, creating proprietary datasets that continuously train and improve the AI models.
- De Novo Therapeutic Protein Design: Ability to create proteins that natural evolution never produced, enabling entirely new mechanisms of action for treating immune-mediated diseases.
- Immunology Pipeline: An advancing pipeline of AI-designed candidates including IgG proteases, next-generation cytokines, and respiratory disease therapeutics targeting high-unmet-need conditions.
- Peer-Reviewed Platform Validation: Published research in PNAS and microPublication Biology, including the ProT-VAE model developed with NVIDIA, demonstrating real-world performance gains in protein stability and function.
Use Cases
- Designing de novo therapeutic proteins with novel mechanisms of action not found in nature for immune-mediated diseases.
- Accelerating drug discovery timelines by using AI to rapidly identify and optimize protein candidates before costly clinical trials.
- Developing next-generation biologics such as IgG proteases and engineered cytokines to overcome limitations of existing treatments.
- Partnering with pharmaceutical companies to apply the EvoGen/EvoLab platform to their target protein design challenges.
- Advancing research into protein engineering through peer-reviewed publications and collaborative projects with AI infrastructure partners like NVIDIA.
Pros
- Closed-Loop AI-Driven Discovery: The integrated design-build-test cycle between EvoGen and EvoLab accelerates candidate development and continuously improves the AI model with proprietary experimental data.
- Validated by Peer-Reviewed Science: Publications in top journals and collaboration with NVIDIA lend strong scientific credibility to the platform's capabilities and results.
- Addresses High-Unmet Medical Need: Focuses on immune-mediated diseases where current biologics fail or lose efficacy over time, targeting a large and growing patient population.
Cons
- Not a Consumer or Developer Tool: Evozyne is a biotech company, not a software product — external access to its AI platform is not publicly available and is limited to partnerships.
- Early Clinical Stage: Pipeline candidates are still advancing toward clinical evaluation, meaning no approved therapeutics are available yet and timelines carry inherent biotech development risk.
Frequently Asked Questions
What is Evozyne?
Evozyne is an AI-native biotechnology company based in Chicago, IL, that uses generative AI to design novel therapeutic proteins for immune-mediated diseases. Its platform combines an AI design engine (EvoGen) with a high-throughput experimental lab (EvoLab).
What diseases does Evozyne focus on?
Evozyne focuses on immune-mediated diseases with high unmet need — conditions where current biologics and small molecules fail or lose efficacy over time. Its pipeline includes IgG proteases, next-generation cytokines, and respiratory disease candidates.
How does Evozyne's AI platform work?
EvoGen, Evozyne's AI engine, learns the relationship between protein sequences and biological function. It designs optimized protein candidates, which are then synthesized and tested at scale in EvoLab. The resulting data loops back to improve the AI models in an iterative cycle.
Has Evozyne's platform been scientifically validated?
Yes. Evozyne has published peer-reviewed research, including the ProT-VAE model (developed with NVIDIA) in PNAS, and a study on ML-guided synthetic proteins with superior thermotolerance in microPublication Biology.
Can companies partner with Evozyne?
Yes, Evozyne is open to partnerships. Interested organizations can reach out through the Partnerships section of their website to explore collaboration opportunities leveraging their AI protein design platform.
